2023 FUTURES: RNA targeted Therapeutics Sessions Part 2
Continued updates from relevant companies in the space. These presentations will be followed by a moderated Q&A opportunity.

Mark Stahl, MD, PhD
Senior Medical Director, Clinical Development
Avidity Biosciences



Dania Porco, MS, MBA, CGC
Director in Clinical Science BioMarin Pharmaceutical Inc.

